Transforming the diagnostic pathway from specimen collection and management to improved laboratory performance, enabling customers to deliver accurate diagnoses.

The portfolio is integrated in both clinical and lab processes and includes:

Specimen Management – Innovative solutions to acquire and transport specimen types ensuring sample quality.

Microbiology – Transforming microbiology labs through integrated solutions.

Molecular, Women’s Health & Cancer – Automated tools that advance infectious disease diagnosis.

Point of Care – Rapid immunoassay platform for decentralised care.

The Commission leads and coordinates national improvements in the safety and quality of health care.

• Developing national safety and quality standards
• Developing clinical care standards
• Coordinating work to improve outcomes
• Providing publications and resources

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people.

The company is committed to advancing innovative medicines to prevent and treat lifethreatening diseases, including HIV, viral hepatitis and cancer.

Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

Based in Melbourne, Gilead Sciences Australia and New Zealand employs over 100 people.

Every day, Pfizer colleagues work to provide improved health outcomes by supporting preventions, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as a World leading biopharmaceutical company, we collaborate with healthcare providers, governments and local communities to support and expand access to reliable and affordable health care for the community. Pfizer Anti-Infectives has undertaken to prioritise research, education and drug development initiatives designed to help address the critical need for novel antimicrobial medicines, a better understanding of bacterial antibiotic resistance and projects to enhance antimicrobial stewardship.

AstraZeneca is a science-led, patient-centered, global pharmaceutical company transforming the future of healthcare by unlocking the power of what science can do – for people, society and the planet. AstraZeneca has been transforming the local treatment landscape for Australians and New Zealanders living with cancer and chronic disease for almost 70 years. In Vaccines & Immune Therapies, our ambition is to develop and deliver transformative vaccines and antibodies, providing long-lasting immunity for millions of people where the burden of disease is greatest.

bioMérieux, a global leader in in-vitro diagnostics, present in more than 160 countries worldwide. For 60 years, bioMérieux is driven by a pioneering spirit and unrelenting commitment to provide innovative diagnostic solutions that improve patient health. The patient is at the centre of our strategy of developing products with high medical and economic value. Our extensive Antimicrobial Stewardship (AMS) diagnostics range supports appropriate antibiotic use, helping to preserve their efficacy and curb antibiotic resistance. Putting diagnostics at the heart of Antimicrobial Stewardship helps drive informed therapy decisions, providing actionable results to the clinician at every stage of the patient’s healthcare pathway: from initiation of antibiotic therapy, to treatment adjustment and optimization and finally for antibiotic discontinuation.

Cepheid provides fast, accurate molecular diagnostics through its GeneXpert® systems.

Portfolio includes respiratory infections, virology, sexual health, tuberculosis, oncology and more.

Link Healthcare, a subsidiary of Clinigen, is a specialist pharmaceutical and medical technology company dedicated to connecting prescribers with medicine that matters. Operating across APAC, we provide access to critical medicines through clinical trial supply, early access programs, unregistered and registered medicines, and sourcing solutions for drug shortages. Our diverse portfolio includes specialist products such as Trexject and Voquily. Committed to improving patient outcomes, we work closely with healthcare professionals to ensure timely access to life-changing therapies. Learn more at www.linkhealthcare.com.au

The National Centre for Antimicrobial Stewardship (NCAS) is Australia’s leading multidisciplinary research hub dedicated to improving antimicrobial use across human and animal health.

Based at the Peter Doherty Institute, NCAS brings together infectious disease physicians, microbiologists, veterinarians, pharmacists, epidemiologists and more.

RMH Guidance Group works to improve antimicrobial prescribing through evidence-based tools and analysis, including the National Antimicrobial Prescribing Survey (NAPS).